Shionogi deepens ALS real-world data strategy after $2.5bn Radicava acquisition
Read how Shionogi’s NeuroBANK partnership could shape Radicava evidence, ALS trial design and real-world treatment research.
Pharma & Biotech
Pharma & Biotech
Could OM Pharma’s Broncho-Vaxom study change how clinicians assess recurrent RTI prevention?
Find out how OM Pharma’s Broncho-Vaxom data could reshape RTI prevention, real-world evidence and non-antibiotic care strategies.
Medical Devices & Diagnostics
Did OM1 just prove AI-powered real-world evidence can survive FDA scrutiny?
FDA-grade evidence is getting bigger and harder to collect. OM1’s Hologic study shows how AI may change medtech submissions.
Pharma & Biotech
Why Lundbeck’s INFUSE study could broaden how migraine treatment success is measured
Lundbeck’s new Vyepti data highlight migraine-related cognitive symptom gains. Read what the INFUSE study could change for clinicians and the CGRP market.
Pharma & Biotech
Real-world data meets legal limits as Bayer targets ERLEADA claims in prostate cancer
Bayer’s lawsuit against Johnson and Johnson raises critical questions about real-world evidence and oncology marketing. Read what this means for drug claims.
Pharma & Biotech
What TG Therapeutics’ ACTRIMS strategy signals about the next competitive phase in anti-CD20 multiple sclerosis therapy
Find out how TG Therapeutics’ ACTRIMS strategy reshapes competition in anti-CD20 multiple sclerosis therapy and what clinicians and regulators are watching next.